Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Distribution of HLA-B alleles in a Ugandan HIV-infected adult population: NORA pharmacogenetic substudy of DART.

Tropical medicine & international health : TM & IH - 1 Feb 2011

Munderi Paula, Snowden Wendy B, Walker Ann Sarah, Kityo Cissy, Mosteller Michael, Kabuye Geoffrey, Thoofer Navdeep K, Ssali Francis, Gilks Charles F, Hughes Arlene R

Abstract excerpt

OBJECTIVES: To determine the frequencies of HLA-B alleles in Ugandan patients in the NORA substudy of the DART trial and to compare HLA-B allele frequencies in those with and without clinically diagnosed hypersensitivity reaction (HSR). METHODS: DNA-based HLA-B genotyping was used to determine HLA alleles in 247 participants who received abacavir, including all six participants ('cases') with clinically diagnosed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to Dideoxynucleosides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Double-Blind Method

Share to Drug Hypersensitivity

Share to HIV Infections

Share to HLA-B Antigens

Share to Nevirapine

Share to Uganda

Source

Identifiers

PMID: 21091860
DOI: 10.1111/j.1365-3156.2010.02688.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Distribution of HLA-B alleles in a Ugandan HIV-infected adult population: NORA pharmacogenetic substudy of DART.PMID 21091860Read ↗

Prospective epidemiological study of the prevalence of human leukocyte antigen (HLA)-B*5701 in HIV-1-infected UK subjects.Semantic proximity Read ↗

Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing.Semantic proximity Read ↗

HLA-B*57:01 allele prevalence in HIV-infected North American subjects and the impact of allele testing on the incidence of abacavir-associated hypersensitivity reaction in HLA-B*57:01-negative subjectsSemantic proximity Read ↗

HLA-B*5701 screening for hypersensitivity to abacavir.Semantic proximity Read ↗

Prevalence of Human Leukocyte Antigen HLA-B*57:01 in Individuals with HIV in West and Central AfricaSemantic proximity Read ↗

Human leukocyte antigen HLA-B*57:01 status in HIV-1 patients developing hypersensitivity reactions in Benin: a pilot studySemantic proximity Read ↗

Prevalence of human leukocyte antigen HLA-B*57:01 in individuals with HIV in West and Central Africa.Semantic proximity Read ↗

Abacavir adverse reactions related with HLA-B*57: 01 haplotype in a large cohort of patients infected with HIV.Semantic proximity Read ↗

Human leukocyte antigen HLA-B*57:01 status in HIV-1 patients developing hypersensitivity reactions in Benin: a pilot study.Semantic proximity Read ↗

Prevalence of HLA-B*57:01 and complete linkage disequilibrium with HCP5 rs2395029: Prevalence and DetectionSemantic proximity Read ↗

Abacavir Pharmacogenetics – From Initial Reports to Standard of CareSemantic proximity Read ↗

Genetic variations in HLA-B region and hypersensitivity reactions to abacavir.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.